2026 is the year in which the long-term themes, the true drivers of sustainable success for the burgeoning landscape of obesity treatment, prescription medicines and beyond, become apparent.
From 2026 onwards we will see:
- The first oral obesity medicines, but also the first off-patent competition
- Lower prices and greater accessibility than ever before, but also rising concerns about how people successfully maintain their weight loss and realise the benefits of impacts on comorbidities of obesity
- Greater competition, innovative and off patent, from a wider group of players, but increasing need to differentiate in an increasingly complex, segmented market.
- New areas of focus beyond weight loss into new labels reflecting comorbidity benefit, maintenance, and muscle preservation
By joining our speakers, you will learn:
- What we can expect in terms of key events and features of the 2026 obesity treatment availability, obesity medicines and beyond
- The drivers of global obesity market from 2026 to 2030
- Key issues to be aware of and to plan for success in obesity to 2030
Secure your place now
.svg){kind=icon}
